S2B — Syn2bio SA Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End null | Unit | null | null | null | null | null | nullE | nullE | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Syn2bio SA is a Poland-based company, which is primarily engaged in the biotechnology and medical research business sector. The Company is mainly engaged in the development of cardiotracer project. It is a radiopharmaceutical for the diagnosis of heart diseases. It is designed to examine myocardial perfusion as well as diagnose coronary artery disease. It enables detection of myocardial perfusion disorders, assessment of the patient's condition following a heart attack or coronary artery disease and determination of the severity of atherosclerotic lesions in the coronary arteries. The Company also operates Center for Research on New Molecules, a unit that searches for new, innovative pharmaceutical molecules, their further research, registration and introduction to the market as a medical product.
Directors
- Last Annual
- Last Interim
- Incorporated
- August 7th, 2025
- Public Since
- April 15th, 2026
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Warsaw Stock Exchange
- Address
- ul. J. P. Dziekonskiego 3, WARSZAWA, 00-728
- Web
- https://syn2bio.pl/
- Phone
- +48 223270910
- Auditors
Similar to S2B
Bioton SA
Warsaw Stock Exchange
Captor Therapeutics SA
Warsaw Stock Exchange
Genomed SA
Warsaw Stock Exchange
Genomtec SA
Warsaw Stock Exchange
Hyenergy SA
Warsaw Stock Exchange
FAQ
As of Today at 14:33 UTC, shares in Syn2bio SA are trading at PLN31.75. This share price information is delayed by 15 minutes.
Shares in Syn2bio SA last closed at PLN31.75 and the price had moved by over the past 365 days. In terms of relative price strength the Syn2bio SA share price has matched the FTSE Global All Cap Index by over the past year.
There is no consensus recommendation for this security.
Find out moreSyn2bio SA does not currently pay a dividend.
Syn2bio SA does not currently pay a dividend.
Syn2bio SA does not currently pay a dividend.
To buy shares in Syn2bio SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN31.75, shares in Syn2bio SA had a market capitalisation of .
Here are the trading details for Syn2bio SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: S2B
Based on an overall assessment of its quality, value and momentum Syn2bio SA is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Syn2bio SA. Over the past six months, its share price has matched the FTSE Global All Cap Index by .
As of the last closing price of PLN31.75, shares in Syn2bio SA were trading +0.08% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Syn2bio SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN31.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Syn2bio SA's directors